| ACT | artemisinin combination therapy |
| ADI | acceptable daily intake |
| ALA | alpha-linolenic acid; |
| API | active pharmaceutical ingredients |
| ARA | arachidonic acid |
| ATP | adenosine triphosphate |
| BBB | blood–brain barrier |
| Cas9 | CRISPR-associated protein 9 |
| CD44 | cluster of differentiation 44; |
| CMC | critical micellar concentration |
| CPP | cell penetrating peptides |
| CRISPR | clustered regularly interspaced short palindromic repeats |
| DCC | dicyclohexylcarbodiimide |
| DHA | docosahexaenoic acid |
| DMAP | 4-(dimethylamino)pyridine |
| DOTAP | 1,2-dioleoyl-3-trimethylammonium-propane chloride |
| DPA | docosapentaenoic acid |
| DPPC | 1,2-dipalmitoyl-sn-glycero-3-phosphocholine |
| DSC | differential scanning calorimetry |
| DSPE-PEG2000 | 1,2-distearoyl-sn-glycero-3-phosphoethanol-amine-N-amino(polyethylene glycol)2000 |
| ELISA | enzyme-linked immunosorbent assay |
| EPR | enhanced permeability and retention |
| ESR | electron spin resonance |
| EV | extracellular vesicles |
| FDA | US Food and Drug Administration |
| FTIR | Fourier-transform infrared |
| GI | gastrointestinal |
| GIXD | grazing incidence X-ray diffraction |
| GPC | glycerophosphocholine |
| GRAS | generally recognized as safe |
| HA | hyaluronic acid |
| HLD | hydrophilic–lipophilic deviation |
| HSC | hepatic stellate cells |
| HSPC | hydrogenated soybean phosphatidylcholine |
| i.m. | intramuscular |
| i.v. | intravenous |
| ITC | isothermal titration calorimetry |
| LLOD | lower limit of detection |
| LPE | lyso-phosphatidylethanolamine |
| miRNA | micro ribonucleic acid |
| ML-I | mistletoe-lectin-I |
| MM | mixed micelles |
| MM-DDS | mixed micellar drug delivery systems |
| MNBA | 2-methyl-6-nitrobenzoic anhydride |
| MPS | mononuclear phagocytic system |
| mRNA | messenger ribonucleic acid |
| MTP-PE | muramyl tripeptide |
| NAFLD | non-alcoholic fatty liver disease |
| NASH | non-alcoholic steatohepatitis |
| NIR | near-infrared |
| NSAID | non-steroidal anti-inflammatory drugs |
| o/w | oil-in-water |
| OXIL | oxidation-responsive liposomes |
| OxPL | oxidized phospholipids |
| PA | phosphatic acid |
| PC | phosphatidylcholine |
| PE | phosphatidylethanolamine |
| PEG | polyethylene glycol |
| PG | phosphatidylglycerol |
| PI | phosphatidylinositol |
| PLA1 | phospholipase A1 (alternatively A2, B, C, D) |
| PLGA | poly(lactide-co-glycolide) |
| POPC | 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine |
| PRC | Phospholipid Research Center Heidelberg |
| PRR | pattern-recognition-receptor |
| PS | phosphatidylserine |
| PUFA | polyunsaturated fatty acids |
| RNA | ribonucleic acid |
| s.c. | subcutaneous |
| SANP | self-assembling nanoparticle |
| SAXS | small angle X-ray scattering |
| SEDDS | self-emulsifying drug delivery systems |
| siRNA | small interfering ribonucleic acid |
| SLN | solid-lipid nanoparticles |
| SM | sphingomyelin |
| SNEDDS | self nano-emulsifying drug delivery systems |
| SPM | specialized pro-resolving mediators |
| TAM | tumor-associated macrophages |
| TB | tuberculosis |
| TEL | tetraether lipid |
| TRXF | total reflection X-ray fluorescence |
| TSL | temperature-sensitive liposomes |
| USL | ultrasound-sensitive liposomes |
| USP | United States Pharmacopeia |
| w/o | water-in-oil |
| WHO | World Health Organization |